Center for Cancer and Blood Disorders, PC

Bethesda, Maryland 20817-7847

0 studies enrolling now · 8 studies all time

What they study most

Breast Cancer, Breast Tumor, Cancer of the Breast, Carcinoma, Non-Small-Cell Lung, Chronic Lymphocytic Leukemia, DLBCL Transformed From Indolent Lymphoma, Diffuse Large B-cell Lymphoma, Diffuse Large-Cell Lymphoma, Estrogen Receptor- Negative Breast Cancer, Follicular Grade 3 Lymphoma, Giant Cell Glioblastoma, Glioblastoma

Studies at this site

• A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin — Completed
• Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant — Completed
• Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia — Stopped early
• Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) — Completed
• Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma — Completed
• A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) — Completed
• TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer — Completed
• Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer — Completed